Total Payments
$2,540
2023 Payments
$297.21
Companies
21
Transactions
186
Medicare Patients
1,100
Medicare Billing
$150,467
Payment Breakdown by Category
Food & Beverage$2,540 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,540 | 186 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biohaven Pharmaceuticals, Inc. | $438.57 | 49 | $0 (2021) |
| Biohaven Pharmaceutical Holding Company Ltd. | $354.00 | 33 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $311.60 | 21 | $0 (2023) |
| ABBVIE INC. | $272.08 | 21 | $0 (2023) |
| Biogen, Inc. | $133.01 | 7 | $0 (2023) |
| EMD Serono, Inc. | $121.70 | 5 | $0 (2023) |
| Horizon Therapeutics plc | $113.40 | 5 | $0 (2023) |
| Neurocrine Biosciences, Inc. | $104.41 | 5 | $0 (2022) |
| Eisai Inc. | $102.47 | 6 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $101.56 | 6 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $297.21 | 14 | ABBVIE INC. ($76.91) |
| 2022 | $828.81 | 63 | Biohaven Pharmaceutical Holding Company Ltd. ($354.00) |
| 2021 | $1,128 | 92 | Biohaven Pharmaceuticals, Inc. ($426.80) |
| 2020 | $285.96 | 17 | Neurocrine Biosciences, Inc. ($67.58) |
All Payment Transactions
186 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/11/2023 | EMD Serono, Inc. | MAVENCLAD (Drug) | Food and Beverage | Cash or cash equivalent | $36.68 | General |
| Category: Neurology | ||||||
| 06/29/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $12.74 | General |
| Category: NEUROSCIENCE | ||||||
| 05/30/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $14.04 | General |
| Category: NEUROSCIENCE | ||||||
| 05/11/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: NEUROSCIENCE | ||||||
| 05/04/2023 | EMD Serono, Inc. | MAVENCLAD (Drug) | Food and Beverage | Cash or cash equivalent | $30.98 | General |
| Category: Neurology | ||||||
| 04/26/2023 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $29.07 | General |
| Category: Central Nervous System | ||||||
| 04/20/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: UPLIZNA | ||||||
| 04/06/2023 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $19.94 | General |
| Category: Neurology | ||||||
| 04/05/2023 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: Central Nervous System | ||||||
| 03/22/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: NEUROSCIENCE | ||||||
| 03/07/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: NEUROSCIENCE | ||||||
| 02/07/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $29.97 | General |
| Category: UPLIZNA | ||||||
| 01/19/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: Rare Disease | ||||||
| 01/04/2023 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: Neurology | ||||||
| 12/06/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $8.51 | General |
| Category: PRIMARY CARE | ||||||
| 12/01/2022 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $24.41 | General |
| 11/30/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: NEUROSCIENCE | ||||||
| 11/22/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $13.29 | General |
| Category: PRIMARY CARE | ||||||
| 11/22/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $1.89 | General |
| Category: PRIMARY CARE | ||||||
| 11/15/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: NEUROSCIENCE | ||||||
| 11/10/2022 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $26.47 | General |
| Category: UPLIZNA | ||||||
| 11/03/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $5.14 | General |
| Category: NEUROSCIENCE | ||||||
| 11/02/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $10.93 | General |
| Category: PRIMARY CARE | ||||||
| 11/02/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $9.70 | General |
| Category: PRIMARY CARE | ||||||
| 11/01/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $11.57 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 153 | 202 | $40,780 | $20,043 |
| 2022 | 6 | 326 | 424 | $89,865 | $46,178 |
| 2021 | 6 | 339 | 441 | $93,895 | $51,267 |
| 2020 | 7 | 282 | 338 | $69,435 | $32,979 |
Total Patients
1,100
Total Services
1,405
Medicare Billing
$150,467
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 85 | 130 | $22,100 | $10,569 | 47.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 29 | $6,525 | $3,736 | 57.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $5,525 | $2,902 | 52.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $6,630 | $2,836 | 42.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 122 | 196 | $33,320 | $17,714 | 53.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 65 | 65 | $21,125 | $9,990 | 47.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 65 | 65 | $16,575 | $8,371 | 50.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 41 | 54 | $12,150 | $7,055 | 58.1% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 14 | 21 | $3,360 | $1,700 | 50.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 19 | 23 | $3,335 | $1,349 | 40.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 130 | 216 | $36,720 | $20,611 | 56.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 74 | 74 | $24,050 | $13,156 | 54.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 74 | 74 | $18,870 | $9,222 | 48.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 28 | 37 | $8,325 | $5,223 | 62.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 20 | 23 | $3,210 | $1,593 | 49.6% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 13 | 17 | $2,720 | $1,461 | 53.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 83 | 83 | $21,165 | $10,508 | 49.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 74 | 107 | $18,190 | $8,805 | 48.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 41 | 41 | $13,325 | $6,342 | 47.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 41 | 52 | $6,240 | $3,068 | 49.2% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2020 | 18 | 28 | $4,480 | $2,228 | 49.7% |
| 95909 | Nerve transmission studies, 5-6 studies | Office | 2020 | 11 | 11 | $4,235 | $1,062 | 25.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 14 | 16 | $1,800 | $967.13 | 53.7% |
About Dr. Michael Mark, MD
Dr. Michael Mark, MD is a Neurology healthcare provider based in Millsboro, Delaware. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1821082892.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Mark, MD has received a total of $2,540 in payments from pharmaceutical and medical device companies, with $297.21 received in 2023. These payments were reported across 186 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($2,540).
As a Medicare-enrolled provider, Mark has provided services to 1,100 Medicare beneficiaries, totaling 1,405 services with total Medicare billing of $150,467. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Millsboro, DE
- Active Since 09/07/2005
- Last Updated 04/09/2013
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1821082892
Products in Payments
- NURTEC ODT (Drug) $792.57
- ZEPOSIA (Drug) $202.57
- QULIPTA (Drug) $185.94
- AJOVY (Biological) $176.13
- AUSTEDO (Drug) $135.47
- UPLIZNA (Drug) $113.40
- AIMOVIG (Biological) $97.12
- UBRELVY (Drug) $86.14
- Fycompa (Drug) $82.53
- INGREZZA (Drug) $69.41
- MAVENCLAD (Drug) $67.66
- RADICAVA (Drug) $66.10
- VUMERITY (Drug) $48.29
- APTIOM (Drug) $42.08
- ULTOMIRIS (Biological) $40.60
- VYEPTI (Biological) $38.92
- TYSABRI (Biological) $37.29
- Leqembi (Drug) $19.94
- AVONEX (Biological) $19.70
- ONGENTYS (Drug) $18.79
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.